中国新药杂志

特发性肺纤维化治疗药物研究进展

PDF下载

姜秋燕 ¹ , 梁庆 ¹ , 高劭妍 ¹ , 李霄鹤 ¹^,² , 黄慧 ³ , 周红刚 ¹^,²

中国新药杂志 | 综述 2021,30(14): 1274-1281

收起

中国新药杂志 |综述 2021 , 30 (14) : 1274 -1281

特发性肺纤维化治疗药物研究进展

全屏

姜秋燕¹, 梁庆¹, 高劭妍¹, 李霄鹤¹^,², 黄慧³, 周红刚¹^,²

作者信息

¹南开大学药学院，南开大学药物化学生物学国家重点实验室，天津　300350

²天津国际生物医药联合研究院，天津　300070

³中国医学科学院北京协和医学院北京协和医院呼吸与危重症医学科，北京　100730

通讯作者:

周红刚，男，博士，副教授，主要从事药理学研究。E-mail：honggang.zhou@nankai.edu.cn。

作者简介:

姜秋燕，女，硕士研究生，主要从事药理学研究。E-mail：780866419@qq.com。

Development of therapeutic drugs for idiopathic pulmonary fibrosis

Qiu-yan JIANG¹, Qing LIANG¹, Shao-yan GAO¹, Xiao-he LI¹^,², Hui HUANG³, Hong-gang ZHOU¹^,²

Affiliations

¹College of Pharmacy, Nankai University, State Key Lab of Medicinal Chemical Biology, Tianjin 300350, China

²Tianjin International Joint Academy of Biomedicine, Tianjin 300070, China

³Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

出版时间: 2021-07-30

文章导航

摘要

收起

特发性肺纤维化（idiopathic pulmonary fibrosis，IPF）是最常见、致命性、病因不明的间质性肺病，目前认为是反复的肺泡上皮细胞损伤引起的异常修复导致肺功能丧失的过程。目前全球范围内仅有吡非尼酮和尼达尼布被批准用于治疗IPF，抗肺纤维化药物治疗手段仍亟待开发。由于已上市药物的药动学以及安全性资料较为详尽，研发周期大大缩短，“老药新用”策略的出现给研究者们带来了希望。本文就已上市的不同种类药物在抗肺纤维化中的基础研究进行汇总，为抗肺纤维化药物开发提供参考。

关键词

特发性肺纤维化 / 上市药物 / 新适应证开发 / 基础研究

Abstract

收起

Idiopathic pulmonary fibrosis (IPF) is the most common, fatal interstitial lung disease with unknown etiology. The current hypothesis is that sustained injury imposed on alveolar epithelial cells leads to aberrant wound healing and finally pulmonary function failure. The unknown pathogenesis heightens the difficulty for anti-fibrosis drug development. Only two drugs, pirfenidone and nintedanib, are approved for IPF treatment, and medical therapies against IPF are still in urgent need. Now researchers are focusing on new indications development for approved drugs since they have relatively detailed pharmacokinetics and safety data. Thus, effective drugs will rapidly go to clinical trials, and the development cycle will be greatly shortened. Here we summarize the basic science studies for different types of approved drugs against IPF and hope to provide reference for development of anti-fibrosis drugs.

Key words

idiopathic pulmonary fibrosis / approved drugs / new indications development / basic science study

引用本文

姜秋燕, 梁庆, 高劭妍, 李霄鹤, 黄慧, 周红刚. 特发性肺纤维化治疗药物研究进展. 中国新药杂志, 2021 , 30 (14) : 1274 -1281 .

Qiu-yan JIANG, Qing LIANG, Shao-yan GAO, Xiao-he LI, Hui HUANG, Hong-gang ZHOU. Development of therapeutic drugs for idiopathic pulmonary fibrosis[J]. Chinese Journal of New Drugs, 2021 , 30 (14) : 1274 -1281 .

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

PUGLISI S, TORRISI SE, GIULIANO R, et al. What we know about the pathogenesis of idiopathic pulmonary fibrosis[J]. Semin Respir Crit Care Med, 2016, 37(3): 358-367.

[2]

WOLTERS PJ, COLLARD HR, JONES KD. Pathogenesis of idiopathic pulmonary fibrosis[J]. Annu Rev Pathol, 2014, 9(1): 157-179.

[3]

THANNICKAL VJ. Mechanistic links between aging and lung fibrosis[J]. Biogerontology, 2013, 14(6): 609-615.

[4]

MARTINEZ FJ, COLLARD HR, PARDO A, et al. Idiopathic pulmonary fibrosis[J]. Nat Rev Dis Primers, 2017, 3: 17074.

[5]

SGALLA G, IOVENE B, CALVELLO M, et al. Idiopathic pulmonary fibrosis: pathogenesis and management[J]. Respir Res, 2018, 19(1): 32.

[6]

LIU YM, NEPALI K, LIOU JP. Idiopathic pulmonary fibrosis: current status, recent progress, and emerging targets[J]. J Med Chem, 2017, 60(2): 527-553.

[7]

SOMOGYI V, CHAUDHURI N, TORRISI SE, et al. The therapy of idiopathic pulmonary fibrosis: what is next?[J]. Eur Respir Rev, 2019, 28(153): 190021.

[8]

VANCHERI C. Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology[J]. Proc Am Thorac Soc, 2012, 9(3): 153-157.

[9]

KOTILIGAM D, LAZAR AJ, POLLOCK RE, et al. Desmoid tumor: a disease opportune for molecular insights[J]. Histol Histopathol, 2008, 23(1): 117-126.

[10]

KÖNIGSHOFF M. Lung cancer in pulmonary fibrosis: tales of epithelial cell plasticity[J]. Respiration, 2011, 81(5): 353-358.

[11]

AONO Y, NISHIOKA Y, INAYAMA M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice[J]. Am J Respir Crit Care Med, 2005, 171(11): 1279-1285.

[12]

DANIELS CE, WILKES MC, EDENS M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis[J]. J Clin Invest, 2004, 114(9): 1308-1316.

[13]

VUORINEN K, GAO F, OURY TD, et al. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia[J]. Exp Lung Res, 2007, 33(7): 357-373.

[14]

CHILAKAPATI SR, SERASANAMBATI M, VISSAVAJJHALA P, et al. Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib[J]. Exp Lung Res, 2015, 41(4): 173-188.

[15]

RUAN H, LV Z, LIU SS, et al. Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-β1 signalling pathway[J]. J Pharm Pharmacol, 2020, 72(1): 44-55.

[16]

HARDIE WD, DAVIDSON C, IKEGAMI M, et al. EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis[J]. Am J Physiol Lung Cell Mol Physiol, 2008, 294(6): L1217-L1225.

[17]

ISHII Y, FUJIMOTO S, FUKUDA T. Gefitinib prevents bleomycin-induced lung fibrosis in mice[J]. Am J Respir Crit Care Med, 2006, 174(5): 550-556.

[18]

LI L, LIN C, ZHENG LX, et al. Gefitinib inhibits bleomycin-induced pulmonary fibrosis via alleviating the oxidative damage in mice[J]. Oxid Med Cell Longev, 2018, 2018: 1-12.

[19]

HUANG X, WANG WC, YUAN HQ, et al. Sunitinib, a small-molecule kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice[J]. Tohoku J Exp Med, 2016, 239(4): 251-261.

[20]

QU YB, ZHANG L, KANG ZC, et al. Ponatinib ameliorates pulmonary fibrosis by suppressing TGF-β1/Smad3 pathway[J]. Pulm Pharmacol Ther, 2015, 34: 1-7.

[21]

YILMAZ O, OZTAY F, KAYALAR O. Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice[J]. Growth Factors, 2015, 33(5-6): 366-375.

[22]

ABDALLA M, THOMPSON L, GURLEY E, et al. Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF pathway[J]. Eur J Pharmacol, 2015, 769: 134-142.

[23]

KANEMARU R, TAKAHASHI F, KATO M, et al. Dasatinib suppresses TGFβ-mediated epithelial-mesenchymal transition in alveolar epithelial cells and inhibits pulmonary fibrosis[J]. Lung, 2018, 196(5): 531-541.

[24]

CRUZ FF, HORTA LF, MAIA LDE A, et al. Dasatinib reduces lung inflammation and fibrosis in acute experimental silicosis[J]. PLoS One, 2016, 11(1): e0147005.

[25]

CARNEIRO PJ, CLEVELARIO AL, PADILHA GA, et al. Bosutinib therapy ameliorates lung inflammation and fibrosis in experimental silicosis[J]. Front Physiol, 2017, 8(3): 159.

[26]

CHEN YL, ZHANG X, BAI J, et al. Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation[J]. Cell Death Dis, 2013, 4(6): e665.

[27]

GU YY, HUANG B, YANG YF, et al. Ibrutinib exacerbates bleomycin-induced pulmonary fibrosis via promoting inflammation[J]. Inflammation, 2018, 41(3): 904-913.

[28]

TABATA C, TABATA R, KADOKAWA Y, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice[J]. J Immunol, 2007, 179(1): 708-714.

[29]

DONG XY, LI X, LI MH, et al. Inhibitory effects of thalidomide on bleomycin-induced pulmonary fibrosis in rats via regulation of thioredoxin reductase and inflammations[J]. Am J Transl Res, 2017, 9(10): 4390-4401.

[30]

ZHOU XL, XU P, CHEN HH, et al. Thalidomide inhibits TGF-β1-induced epithelial to mesenchymal transition in alveolar epithelial cells via smad-dependent and smad-independent signaling pathways[J]. Sci Rep, 2017, 7(1): 14727.

[31]

BIAN C, QIN WJ, ZHANG CY, et al. Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner[J]. Free Radic Biol Med, 2018, 129: 446-453.

[32]

FARKAS L, GAULDIE J, VOELKEL NF, et al. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors[J]. Am J Respir Cell Mol Biol, 2011, 45(1): 1-15.

[33]

YAO HW, ZHU JP, ZHAO MH, et al. Losartan attenuates bleomycin-induced pulmonary fibrosis in rats[J]. Respiration, 2006, 73(2): 236-242.

[34]

GUO F, SUN YB, SU L, et al. Losartan attenuates paraquat-induced pulmonary fibrosis in rats[J]. Hum Exp Toxicol, 2015, 34(5): 497-505.

[35]

MOHAMMADI-KARAKANI A, GHAZI-KHANSARI M, SOTOUDEH M. Lisinopril ameliorates paraquat-induced lung fibrosis[J]. Clin Chim Acta, 2006, 367(1-2): 170-174.

[36]

BELLAYE PS, YANAGIHARA T, GRANTON E, et al. Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension[J]. Eur Respir J, 2018, 52(2): 1701857.

[37]

ZHU YJ, LIU Y, ZHOU WX, et al. A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice[J]. Respir Res, 2010, 11(1): 34.

[38]

LAMBERS C, ROTH M, JAKSCH P, et al. Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation[J]. Sci Rep, 2018, 8(1): 1087.

[39]

NIKITOPOULOU I, MANITSOPOULOS N, KOTANIDOU A, et al. Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice[J]. Pulm Circ, 2019, 9(4): 2045894019881954.

[40]

KIM JW, RHEE CK, KIM TJ, et al. Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis[J]. Clin Exp Pharmacol Physiol, 2010, 37(11): 1055-1063.

[41]

JIANG CG, HUANG H, LIU J, et al. Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice[J]. Int J Mol Sci, 2012, 13(7): 8293-8307.

[42]

BEI YH, HUA-HUY T, DUONG-QUY S, et al. Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation[J]. Pulm Pharmacol Ther, 2013, 26(6): 635-643.

[43]

MILARA J, ESCRIVÁ J, ORTIZ JL, et al. Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study[J]. Eur Respir J, 2016, 47(6): 1737-1749.

[44]

DU J, ZHU Y, MENG XX, et al. Atorvastatin attenuates paraquat poisoning-induced epithelial-mesenchymal transition via downregulating hypoxia-inducible factor-1 alpha[J]. Life Sci, 2018, 213: 126-133.

[45]

ZHAN TW, TIAN YX, WANG Q, et al. Cangrelor alleviates pulmonary fibrosis by inhibiting GPR17-mediated inflammation in mice[J]. Int Immunopharmacol, 2018, 62: 261-269.

[46]

SHAO SJ, ZHANG XN, DUAN LD, et al. Lysyl hydroxylase inhibition by minoxidil blocks collagen deposition and prevents pulmonary fibrosis via TGF-β₁/Smad3 signaling pathway[J]. Med Sci Monit, 2018, 24: 8592-8601.

[47]

KSEIBATI MO, SHEHATOU GSG, SHARAWY MH, et al. Nicorandil ameliorates bleomycin-induced pulmonary fibrosis in rats through modulating eNOS, iNOS, TXNIP and HIF-1α levels[J]. Life Sci, 2020, 246: 117423.

[48]

SEGGEV JS, GOREN MB, KIRKPATRICK CH. The pathogenesis of trehalose dimycolate-induced interstitial pneumonitis. III. Evidence for a role for T lymphocytes[J]. Cell Immunol, 1984, 85(2): 428-435.

[49]

MOLYNEAUX PL, MAHER TM. Respiratory microbiome in IPF: cause, effect, or biomarker?[J]. Lancet Respir Med, 2014, 2(7): 511-513.

[50]

RICHTER AG, STOCKLEY RA, HARPER L, et al. Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis[J]. Thorax, 2009, 64(8): 692-697.

[51]

MOLYNEAUX PL, COX MJ, WILLIS-OWEN SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2014, 190(8): 906-913.

[52]

FUJITA M, YE Q, OUCHI H, et al. Doxycycline attenuated pulmonary fibrosis induced by bleomycin in mice[J]. Antimicrob Agents Chemother, 2006, 50(2): 739-743.

[53]

FUJITA H, SAKAMOTO N, ISHIMATSU Y, et al. Effects of doxycycline on production of growth factors and matrix metalloproteinases in pulmonary fibrosis[J]. Respiration, 2011, 81(5): 420-430.

[54]

HUA XF, LI XH, LI MM, et al. Doxycycline attenuates paraquat-induced pulmonary fibrosis by downregulating the TGF-β signaling pathway[J]. J Thorac Dis, 2017, 9(11): 4376-4386.

[55]

KALEMCI S, DIRICAN N, CETIN ES, et al. The efficacy of minocycline against methotrexate-induced pulmonary fibrosis in mice[J]. Eur Rev Med Pharmacol Sci, 2013, 17(24): 3334-3340.

[56]

WUYTS WA, WILLEMS S, VOS R, et al. Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model[J]. Exp Lung Res, 2010, 36(10): 602-614.

[57]

TSUBOUCHI K, ARAYA J, MINAGAWA S, et al. Azithromycin attenuates myofibroblast differentiation and lung fibrosis development through proteasomal degradation of NOX4[J]. Autophagy, 2017, 13(8): 1420-1434.

[58]

BIECKER E, et al. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms[J]. J Pharmacol Exp Ther, 2005, 313(3): 952-961.

[59]

TULEK B, KIYAN E, TOY H, et al. Anti-inflammatory and anti-fibrotic effects of sirolimus on bleomycin-induced pulmonary fibrosis in rats[J]. Clin Invest Med, 2011, 34(6): e341.

[60]

SHAO X, LI M, LUO C, et al. Effects of rapamycin against paraquat-induced pulmonary fibrosis in mice[J]. J Zhejiang Univ Sci B, 2015, 16(1): 52-61.

[61]

FAUBERT B, LI KY, CAI L, et al. Lactate metabolism in human lung tumors[J]. Cell, 2017, 171(2): 358-371.

[62]

BERNARD K, LOGSDON NJ, RAVI S, et al. Metabolic reprogramming is required for myofibroblast contractility and differentiation[J]. J Biol Chem, 2015, 290(42): 25427-25438.

[63]

PARA R, ROMERO F, GEORGE G, et al. Metabolic reprogramming as a driver of fibroblast activation in PulmonaryFibrosis[J]. Am J Med Sci, 2019, 357(5): 394-398.

[64]

XIE N, TAN Z, BANERJEE S, et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis[J]. Am J Respir Crit Care Med, 2015, 192(12): 1462-1474.

[65]

ZANK DC, BUENO M, MORA AL, et al. Idiopathic pulmonary fibrosis: aging, mitochondrial dysfunction, and cellular bioenergetics[J]. Front Med (Lausanne), 2018, 5: 10.

[66]

TSAKNIS G, SIEMPOS II, KOPTERIDES P, et al. Metformin attenuates ventilator-induced lung injury[J]. Crit Care, 2012, 16(4): R134.

[67]

CHOI SM, JANG AH, KIM H, et al. Metformin reduces bleomycin-induced pulmonary fibrosis in mice[J]. J Korean Med Sci, 2016, 31(9): 1419-1425.

[68]

LI L, HUANG WT, LI KL, et al. Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway[J]. Oncotarget, 2015, 6(41): 43605-43619.

[69]

SATO N, TAKASAKA N, YOSHIDA M, et al. Metformin attenuates lung fibrosis development via NOX4 suppression[J]. Respir Res, 2016, 17(1): 107.

[70]

RANGARAJAN S, BONE NB, ZMIJEWSKA AA, et al. Metformin reverses established lung fibrosis in a bleomycin model[J]. Nat Med, 2018, 24(8): 1121-1127.

[71]

KHEIROLLAHI V, WASNICK RM, BIASIN V, et al. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis[J]. Nat Commun, 2019, 10(1): 2987.

[72]

SUZUKI T, TADA, GLADSON S, et al. Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition[J]. Respir Res, 2017, 18(1): 177.

[73]

CABRERA-BENITEZ NE, LAFFEY JG, PAROTTO M, et al. Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome[J]. Anesthesiology, 2014, 121(1): 189-198.

[74]

ZHI QM, YANG LT, SUN HC. Protective effect of ambroxol against paraquat-induced pulmonary fibrosis in rats[J]. Intern Med, 2011, 50(18): 1879-1887.

[75]

LI SF, YANG XX, LI WD, et al. N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats[J]. Respiration, 2012, 84(6): 509-517.

[76]

HERRMANN FE, WOLLIN L, WIRTH J, et al. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis[J]. Br J Pharmacol, 2017, 174(21): 3848-3864.

[77]

GAO F, HOBSON AR, SHANG ZM, et al. The prevalence of gastro-esophageal reflux disease and esophageal dysmotility in Chinese patients with idiopathic pulmonary fibrosis[J]. BMC Gastroenterol, 2015, 15(1): 26.

[78]

VUKOVAC L, LOZO M, MISE K, et al. Bronchoalveolar pH and inflammatory biomarkers in newly diagnosed IPF and GERD patients: a case-control study[J]. Med Sci Monit, 2014, 20: 255-261.

[79]

RAGHU G, FREUDENBERGER TD, YANG S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis[J]. Eur Respir J, 2006, 27(1): 136-142.

[80]

WANG Z, BONELLA F, LI W, et al. Gastroesophageal reflux disease in idiopathic pulmonary fibrosis: uncertainties and controversies[J]. Respiration, 2018, 96(6): 571-587.

[81]

LEE JS, RYU JH, ELICKER BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2011, 184(12): 1390-1394.

[82]

GHEBREMARIAM YT, COOKE JP, GERHART W, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis[J]. J Transl Med, 2015, 13: 249.

[83]

COMEGLIO P, FILIPPI S, SARCHIELLI E, et al. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis[J]. J Steroid Biochem Mol Biol, 2017, 168: 26-37.

[84]

ZHAO X, SUN J, SU W, et al. Melatonin protects against lung fibrosis by regulating the hippo/YAP pathway[J]. Int J Mol Sci, 2018, 19(4): 1118.

[85]

YILDIRIM Z, KOTUK M, ERDOGAN H, et al. Preventive effect of melatonin on bleomycin-induced lung fibrosis in rats[J]. J Pineal Res, 2006, 40(1): 27-33.

[86]

ARSLAN SO, ZERIN M, VURAL H, et al. The effect of melatonin on bleomycin-induced pulmonary fibrosis in rats[J]. J Pineal Res, 2002, 32(1): 21-25.

[87]

ZHAO H, WU QQ, CAO LF, et al. Melatonin inhibits endoplasmic Reticulum stress and epithelial-mesenchymal transition during bleomycin-induced pulmonary fibrosis in mice[J]. PLoS One, 2014, 9(5): e97266.

[88]

SUGIZAKI T, TANAKA KI, ASANO T, et al. Idebenone has preventative and therapeutic effects on pulmonary fibrosis via preferential suppression of fibroblast activity[J]. Cell Death Discov, 2019, 5(1): 146.

[89]

TAJIMA S, BANDO M, ISHII Y, et al. Effects of edaravone, a free-radical scavenger, on bleomycin-induced lung injury in mice[J]. Eur Respir J, 2008, 32(5): 1337-1343.

[90]

ZHI Q, SUN H, QIAN X, et al. Edaravone, a novel antidote against lung injury and pulmonary fibrosis induced by paraquat?[J]. Int Immunopharmacol, 2011, 11(1): 96-102.

[91]

WANG XD, DE LAI R, SU XF, et al. Edaravone attenuates lipopolysaccharide-induced acute respiratory distress syndrome associated early pulmonary fibrosis via amelioration of oxidative stress and transforming growth factor-β1/Smad3 signaling[J]. Biochem Biophys Res Commun, 2018, 495(1): 706-712.

[92]

VERMA R, BRAHMANKAR M, KUSHWAH L, et al. Evaluating the inhibitory potential of sulindac against the bleomycin-induced pulmonary fibrosis in wistar rats[J]. Environ Toxicol Pharmacol, 2013, 36(3): 769-778.

[93]

LV XX, WANG XX, LI K, et al. Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents[J]. PLoS One, 2013, 8(7): e68631.

[94]

TOYAMA T, ASANO Y, AKAMATA K, et al. Tamibarotene ameliorates bleomycin-induced dermal fibrosis by modulating phenotypes of fibroblasts, endothelial cells, and immune cells[J]. J Invest Dermatol, 2016, 136(2): 387-398.

[95]

BOYAPALLY R, PULIVENDALA G, BALE S, et al. Niclosamide alleviates pulmonary fibrosis in vitro and in vivo by attenuation of epithelial-to-mesenchymal transition, matrix proteins & Wnt/β-catenin signaling: a drug repurposing study[J]. Life Sci, 2019, 220: 8-20.

[96]

LI Y, SONG DY, BO FY, et al. Diazepam inhibited lipopolysaccharide (LPS)-induced pyroptotic cell death and alleviated pulmonary fibrosis in mice by specifically activating GABAA receptor α4-subunit[J]. Biomedecine Pharmacother, 2019, 118: 109239.

[97]

LI L, ZHAO J, ZHOU L, et al. Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF-β1/Smad3 signaling pathway[J]. Respir Res, 2019, 20(1): 163.

[98]

GONZALEZ-FIERRO A, DUEÑAS-GONZÁLEZ A. Drug repurposing for cancer therapy, easier said than done[J]. Semin Cancer Biol, 2021, 68(1): 123-131.

[99]

MERKT W, BUENO M, MORA AL, et al. Senotherapeutics: Targeting senescence in idiopathic pulmonary fibrosis[J]. Semin Cell Dev Biol, 2020, 101(5): 104-110.

[100]

满红霞, 肖培云, 杨永寿, 等. 特发性肺纤维化的发病机制及药物治疗研究进展[J]. 中国现代应用药学, 2015, 32(8): 1024-1028.

2021年第30卷第14期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-07-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-12-11

基金

作者信息

¹南开大学药学院，南开大学药物化学生物学国家重点实验室，天津　300350

²天津国际生物医药联合研究院，天津　300070

³中国医学科学院北京协和医学院北京协和医院呼吸与危重症医学科，北京　100730

通讯作者:

周红刚，男，博士，副教授，主要从事药理学研究。E-mail：honggang.zhou@nankai.edu.cn。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322181103109132814

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT